drugset / Trial / NCT03106662
Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies
Phase 3
Completed
6 enrolled
Ankara University
The Scientific and Technological Research Council of Turkey · collab
NaSingle-groupOpen-labelTreatment
Summary
Mesenchymal stem cells (MSCs) have been used in the treatment and prevention of graft-versus host disease (GVHD). In this study the investigators aim to present the efficacy of mesenchymal stem cells in graft versus host disease prophylaxis and effect of engraftment in haploidentical recipients. Forty patients aged older than 18 who have indications for haploidentical hematopoietic stem cell transplantation will be included to the study. MSCs will be isolated from donor bone marrows and infused to the patient after conditioning regimen on day +6. If the haploidentical transplantation results improve with MSCs treatment it would be possible to ameliorate the problem of HLA-matched donor paucity in Turkey and prefer haploidentical donors.
Timeline
- Start
- 2014-10
- Primary completion
- 2017-07
- Completion
- 2017-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mesenchymal stem cells | Cell therapy | 2e+08 cells/kg | — |
| Subject | mesenchymal stem cells | Cell therapy | 8e+08 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |